Your browser doesn't support javascript.
loading
Comparative Efficacy and Safety of Amlodipine and Losartan Potassium in Essential Hypertension in a Tertiary Hospital of Bangladesh.
Shimu, R N; Majumder, S; Tarannum, F; Chowdhury, D P; Nahar, A; Afrin, A; Akter, M; Nahar, S; Jahan, S; Hossain, M A.
Afiliación
  • Shimu RN; Dr Rehana Naznin Shimu, Lecturer, Department of Pharmacology, Mymensingh Medical College (MMC), Mymensingh, Bangladesh; E-mail: rehananaznin774@gmail.com.
Mymensingh Med J ; 33(2): 365-372, 2024 Apr.
Article en En | MEDLINE | ID: mdl-38557512
ABSTRACT
Hypertension is a common disorder of major clinical, public health and economic importance. It affects men and women of all ages, and the prevalence is increasing in most countries. Maintenance of blood pressure below 140/90 mm of Hg is recommended by most of the guideline available around the world. Various classes of drugs are being used in the treatment of hypertension. Losartan potassium and amlodipine are two different antihypertensive agents belonging to two different groups used commonly around the world in treating essential hypertension. Losartan potassium is non-peptide Angiotensin-II receptor antagonist. Amlodipine which is the third generation dihydropyridine group of calcium channel blocker. The aim of the study was to compare the efficacy and safety of amlodipine and losartan for the treatment of essential hypertensive patients (18-75 years). A non-randomized comparative observational study was conducted in the Department of Pharmacology and Therapeutics in collaboration with Department of Medicine, Sylhet, MAG Osmani Medical College, Sylhet, Bangladesh from July 2021 to June 2022. In this study non-randomization was in two groups. Group A received amlodipine 5mg daily at morning and Group B received losartan potassium 50mg daily at night. The study parameters were systolic blood pressure (SBP), diastolic blood pressure (DBP), ankle oedema, serum K+ level. The result of treatment outcome was compared between two groups. After treatment the reduction of SBP was 5.19±2.93mm of Hg versus 3.27±1.34mm of Hg (p<0.001); reduction of DBP was 1.7±0.70 mm of Hg versus 0.68 mm of Hg (p<0.001) and serum K+ level 4.22±0.27mmol/L versus 4.21±0.16mmol/L (p<0.719) in amlodipine and losartan group respectively. Amlodipine is more effective than losartan potassium in respect to treatment of essential hypertension. Regarding adverse events losartan potassium causes angioedema, hyperkalemia, headache, dizziness etc. The study concluded that amlodipine is superior to losartan potassium in treating essential hypertension.
Asunto(s)
Buscar en Google
Base de datos: MEDLINE Asunto principal: Hipertensión / Mercurio País/Región como asunto: Asia Idioma: En Revista: Mymensingh Med J Asunto de la revista: MEDICINA Año: 2024 Tipo del documento: Article
Buscar en Google
Base de datos: MEDLINE Asunto principal: Hipertensión / Mercurio País/Región como asunto: Asia Idioma: En Revista: Mymensingh Med J Asunto de la revista: MEDICINA Año: 2024 Tipo del documento: Article